NCT05254197 SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
| NCT ID | NCT05254197 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Brain Tumor, Primary |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2001-01-01 |
| Primary Completion | 2035-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2001-01-01 with a primary completion date of 2035-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.
Eligibility Criteria
Inclusion Criteria for retrospective cohort * Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998 * Asymptomatic at first visit to the hospital * Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit * Patients who have had two or more MRs at least 3 months apart * No previous radiotherapy or radiosurgery for the brain lesion * 18 years old or more Inclusion Criteria for prospective cohort * Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less * Asymptomatic at first visit to the hospital * Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams * No previous radiotherapy or radiosurgery for the brain lesion * 18 years old or more * Patients who agree to participate by written consent Exclusion Criteria * Patients who lost follow-up before the second MR exam * Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam * Patients suspected to have other than a neoplasm at follow-up MR exams
Contact & Investigator
Chul-Kee Park, MD PhD
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT05254197 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor, Primary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05254197 currently recruiting?
Yes, NCT05254197 is actively recruiting participants. Contact the research team at nsckpark@snu.ac.kr for enrollment information.
Where is the NCT05254197 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05254197 clinical trial?
NCT05254197 is sponsored by Seoul National University Hospital. The principal investigator is Chul-Kee Park, MD PhD at Seoul National University Hospital. The trial plans to enroll 3,000 participants.